Item 2.02 Results of Operations and Financial Condition

On January 13, 2022, Salona Global Medical Device Corporation (the "Company") issued a press release announcing operating and financial highlights for the third quarter ended November 30, 2021. In this press release, the Company also provided information about its conference call intended to take place January 18, 2022 at 4:45 pm. EST at which time the Company intends to provide a business update and discuss its third quarter ended November 30, 2021. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated in this Item 2.02 by reference.

The information furnished pursuant to Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Richard Mejia

On January 12, 2022 Richard Mejia resigned as Interim Chief Financial Officer.

Appointment of Melissa Polesky-Meyrowitz, CPA

On January 12, 2022, the Company appointed Melissa Polesky-Meyrowitz, CPA as its Chief Financial Officer, effective immediately. Ms. Polesky-Meyrowitz is a certified public accountant (CPA) and received her BBA in accounting from Hofstra University. She has over ten years' experience in accounting and taxation. She was previously an International Tax Services Supervisor at RSM, LLP and a US Tax Compliance and Advisory Manager at Richter LLP located in Toronto, Canada. From September 20, 2021 until January 12, 2022 Ms. Polesky-Meyrowitz was the Company's senior controller.

In connection with her appointment, the Company and Ms. Polesky-Meyrowitz have agreed that Ms. Polesky-Meyrowitz will be employed on an at-will basis and receive $14,500 monthly as compensation. Additionally, pursuant to the Company's 2021 Stock Option Plan, Ms. Polesky-Meyrowitz has been granted options to acquire up to an aggregate of 150,000 shares of the Company's common shares at an exercise price exercise price equal to the closing price of the common shares of the Corporation on the TSX Venture Exchange on the second trading day after the Company files its Quarterly Report on Form 10-Q for the period ended November 30, 2021. The options will be subject to a TSXV Venture Exchange four-month hold and will ?expire five years from the date of grant.

There are no related-party transactions in which Ms. Polesky-Meyrowitz or any of her immediate family members has an interest that would require disclosure under Item 404(a) of Regulation S-K.

Item 9.01 Financial Statements and Exhibits.



  (d) Exhibits

                 Press Release of Salona Global Medical
        99.1   Device Corporation dated January 13,
               2022.
      104      Cover Page Interactive Data File
               (formatted as Inline XBRL)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses